This article is more than 5 years old. Information may no longer be current.
Phase 1b/2a study initiated with integrin peptide therapy for wet AMD
Click Here to Manage Email Alerts
FORT LAUDERDALE, Fla. — An integrin peptide therapy has begun a phase 1b/2a study for the treatment of wet age-related macular degeneration, according to a speaker here.
"Having completed the first human study in end-stage [diabetic macular edema] patients, a phase 1b/2a study with ALG-1001 (Allegro Ophthalmics) is currently in progress," David S. Boyer, MD, said at the Association for Research in Vision and Ophthalmology meeting. "This 6-month, dose-ranging phase 1b/2a study is in wet AMD (as opposed to DME) with the primary goals of safety, efficacy, optimal dosage and duration of effect."
The first subject was enrolled in April, and the study now includes 30 subjects with moderate wet AMD, Dr. Boyer said.
Integrin peptide therapy is an emerging new class of treatment for vascular eye diseases, Dr. Boyer said, and it may provide additional options and patient benefits compared with current anti-VEGF treatment.
- Disclosure: Dr. Boyer receives financial support, is a consultant with and receives other reimbursements from Alcon, Allergan, Genentech and Regeneron. He is a consultant with Allegro, Neurotech and Novartis/QLT. He receives financial support from iCo. He receivers other reimbursements from Novartis and Pfizer.